Abstract. The active form of the small GTPase RAS binds to downstream effectors to promote cell growth and proliferation. RAS signal enhancement contributes to tumorigenesis, invasion, and metastasis in various different cancers. HRAS proto-oncogene GTPase (HRAS), one of the RAS isoforms, was the first human oncogene for which mutations were reported in T24 bladder cancer (BC) cells in 1982, and HRAS mutation or upregulation has been reported in several cancers. According to data from The Cancer Genome Atlas, HRAS expression was significantly upregulated in clinical BC samples compared to healthy samples (P= 0.0024). HRAS expression was also significantly upregulated in BC with HRAS mutation compared to patients without HRAS mutation (P<0.0001). The tumor suppressive effect of salirasib, a RAS inhibitor, has been reported in several cancer types, but only at relatively high concentrations. As such, RAS inhibitors have not been used for clinical applications. The aim of the current study was to investigate the therapeutic potential of targeting HRAS using salirasib and small interfering RNA (siRNA) and to characterize the mechanism by which HRAS functions using recently developed quantitative in vitro proteome-assisted multiple reaction monitoring for protein absolute quantification (iMPAQT), in BC cells. iMPAQT allows measurement of the absolute abundance of any human protein with the high quantitative accuracy. Salirasib and siRNA targeting of HRAS inhibited cell proliferation, migration and invasion in HRAS wild type and HRAS-mutated cell lines. Proteomic analyses revealed that several metabolic pathways, including the oxidative phosphorylation pathway and glycolysis, were significantly downregulated in salirasib-treated BC cells. However, the expression levels of hexokinase 2, phosphoglycerate kinase 1, pyruvate kinase, muscle (PKM)1, PKM2 and lactate dehydrogenase A, which are downstream of RAS and target genes of hypoxia inducible factor-1α, were not notably downregulated, which may explain the high concentration of salirasib required to inhibit cell viability. These findings provide insight into the mechanisms of salirasib, and suggest the need for novel therapeutic strategies to treat cancers such as BC.
Introduction
Bladder cancer (BC) was the 5th most commonly diagnosed cancer and the 8th most common cause of cancer-associated mortality among the 40 European Union countries in 2012.
In that same year, 429,800 new cases of BC were diagnosed, and 165,000 patients succumbed to BC worldwide (1,2). The 5-year survival rate of patients with BC has improved by only a small percentage during the last 30 years according to the National Cancer Institute program Surveillance, Epidemiology and End Results (3) . One factor in the lack of improvement in BC survival rates is the limited efficacy of cisplatin-based combination chemotherapy (4) . Thus, innovative therapeutic strategies are required to improve BC outcomes.
RAS proteins are small molecular weight GTPases that couple extracellular signals to intracellular effector pathways. Mammalian cells encode three closely related RAS proteins, HRas proto-oncogene GTPase (HRAS), NRAS protooncogene GTPase (NRAS) and KRAS proto-oncogene GTPase (KRAS), which have critical roles in fundamental cellular processes, including proliferation, survival, differentiation, motility and transcription (5) . The RAS pathway is one of the most commonly deregulated pathways in human cancer (6) , and activating mutations in RAS genes occur in ~30% of all tumors (7) . These mutations typically render RAS as constitutively GTP-bound, resulting in activation of downstream effector pathways regardless of extracellular stimulation (6) . Substitution of glycine for valine at amino acid 12 (G12V) is one of the most frequently observed RAS mutations that interferes with GTPase-activating protein-mediated GTP hydrolysis, leading to excess amounts of active GTP-bound RAS. Notably, the type of mutated RAS gene (HRAS, KRAS or NRAS) varies depending on the tumor type; KRAS mutations are frequently detected in pancreatic carcinoma (80-90%) and colorectal carcinoma (30-60%), whereas HRAS mutations are frequent in BC (7-66%) and thyroid cancer (0-60%) (8) .
RAS is considered 'undruggable' because the RAS protein lacks a druggable binding pocket (9, 10) . Additionally, development of specific and competitive nucleotide inhibitors is challenging, because RAS binds nucleotide ligands with high affinity (10) . To overcome these challenges, the RAS antagonist salirasib, also termed farnesylthiosalicylate, was designed to competitively inhibit attachment of GTP-bound RAS to the plasma membrane, which in turn inactivates RAS signaling (11) . Salirasib inhibits all RAS isoforms and inhibits the growth of RAS-driven cancer (11, 12) . Although applications of salirasib have been tested in several clinical trials for cancers other than BC (13) (14) (15) (16) , it exhibited insufficient tumor suppressive effects in trials in which salirasib was the single agent. In addition, relatively high concentrations of salirasib were required to achieve sufficient tumor suppressive effects (17, 18) . Therefore, a more detailed examination of the effects of salirasib is required to understand the mechanism by which salirasib acts on RAS. Recently, Matsumoto et al (19) developed a targeted proteomics platform, in vitro proteomeassisted multiple reaction monitoring for protein absolute quantification (iMPAQT), that analyzes 18,000 human recombinant proteins to enable absolute protein quantification on a genome-wide scale (19) and overcome limitations in quantitative accuracy, reproducibility, and analysis speed associated with conventional analysis methods. Use of iMPAQT allows large-scale and accurate assessment of protein abundances that can influence cellular phenotypes.
In the current study, the therapeutic of potential of HRAS knockdown by salirasib or RNA interference was investigated in two BC cell lines (T24 cells with HRAS G12V mutation and BOY cells without HRAS mutation). Furthermore, newly developed quantitative proteome analysis of BC cells treated with salirasib was performed to elucidate the mechanisms underlying the actions of salirasib toward HRAS.
Materials and methods

Analysis in the BC cohort of The Cancer Genome Atlas (TCGA).
Sequencing data were available for 407 BC samples and 19 normal bladder epithelial samples in TCGA database (tcga-data.nci.nih. gov/tcga/). We used TCGA to analyze HRAS mRNA expression levels in normal and BC tissues and to evaluate differences in HRAS mRNA expression levels according to HRAS mutational status. RNA-Seq by Expectation Maximization software was used for gene expression quantification (20) . Full sequencing information, somatic mutation information, and clinical information were acquired using UCSC Xena (xena.ucsc.ed/) and TCGA. The current study meets publication guidelines provided by TCGA (cancergenome.nih.gov/publications/publicationguidelines).
Cell culture and RNA extraction. Four human BC cell lines were used. T24, KK47 and UMUC cells, which were obtained from the American Type Culture Collection (Manassas, VA, USA), and BOY cells, which were established in our laboratory from a 66-year-old Asian male patient diagnosed with stage III BC with lung metastasis. These cell lines were maintained in the minimum essential Eagle's medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), containing 10% fetal bovine serum (Equitech-Bio, Inc., Kerrville, TX, USA), 50 µg/ml streptomycin, and 50 U/ml penicillin in a humidified atmosphere of 95% air/5% CO 2 at 37˚C. Total RNA was isolated using Isogen (Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer's protocol. The integrity of the RNA was checked with an RNA 6000 Nano assay kit and a 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
A SYBR-Green qPCR-based array approach was used for RT-qPCR. RT was performed using the TaqMan HighCapacity cDNA Reverse Transcription Kit (cat. no. 4368814; Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) under the incubation conditions (25˚C for 10 min, 37˚C for 120 min and 85˚C for 5 min) according to the manufacturer's instructions. The primer set for determination of mRNA expression levels was as follows: HRAS, forward, 5'-ATGACGGAATATAAGCTGGTGGT-3' and reverse, 5'-GGCACGTCTCCCCATCAATG-3'; hypoxia inducible factor-1α (HIF-1α), forward, 5'-GAACGTCGAAAAGAAAA GTCTCG-3' and reverse, 5'-CCTTATCAAGATGCGAACTC ACA-3'; glucuronidase β (GUSB), forward, 5'-CGTCCCACC TAGAATCTGCT-3' and reverse, 5'-TTGCTCACAAAGGT CACAGG-3'. The experimental procedures followed the protocol recommended by the manufacturer. RT-qPCR was performed with 500 ng total RNA using the Power SYBR-Green Master Mix (cat. no. 4367659) with the 7300 Real-time PCR System (both from Applied Biosystems; Thermo Fisher Scientific, Inc.). Amplification specificity was monitored using the dissociation curve of the amplified product. All data values were normalized with respect to GUSB, and the ΔΔCq method was used to calculate the fold-change (21 Cell proliferation, migration, and invasion assays. T24 and BOY cells were transfected with 10 nM siRNA by reverse transfection. Cells were seeded in 96-well plates with 3x10 3 cells/well for XTT assays. After 72 h, cell proliferation was determined using a Cell Proliferation Kit II (Roche Diagnostics GmbH, Mannheim, Germany) as described previously (22) . Cell migration activity was evaluated with wound healing assays. Cells were plated in 6-well plates at 2x10 5 cells per well, and after 48 h of transfection the cell monolayer was scraped using a P-20 micropipette tip. The initial (0 h) and residual gap length 18 h after wounding were calculated from photomicrographs as previously described (22) . Cell invasion assays were performed using modified Boyden chambers consisting of Matrigel-coated Transwell membrane filter inserts with 8-µM pores in 24 well tissue culture plates (BD Biosciences, San Jose, CA, USA). At 72 h after transfection, cells were plated in 24-well plates at 1x10 5 cells/well. Minimum essential Eagle's medium containing 10% fetal bovine serum (Equitech-Bio, Inc.) in the lower chamber served as the chemoattractant, as described previously (22) . Medium Eagle fetal bovine serum and cells were prepared in the upper chamber and incubated for 24 h.
Western blot analysis. Cells were harvested 72 h after transfection, and lysates were prepared in radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.) containing protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA). Proteins were quantified by Bradford method using BioPhotometer (Eppendorf, Hamburg, Germany). Proteins (50 µg) were separated by NuPAGE on 4-12% bis-tris gels (Invitrogen; Thermo Fisher Scientific, Inc.) and transferred to polyvinylidene difluoride membranes. Following blocking in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) with 5% nonfat dry milk for 15 min at 25˚C, membranes were washed four times in TBS-T and incubated with primary antibodies overnight at 4˚C. Immunoblotting was performed with diluted rabbit polyclonal anti-HRAS antibodies (1:1,000; cat. no. GTX116041; GeneTex, Inc., Irvine, CA, USA), goat polyclonal anti-HIF-1α antibodies (1:1,000; cat. no. AF1935; R&D Systems, Inc., Minneapolis, MN, USA) and rabbit polyclonal anti-β-actin antibodies (1:1,000; cat. no. bs-0061R; BIOSS, Beijing, China) according to the manufacturer's instructions for each antigen. The secondary antibodies were peroxidase-labelled anti-rabbit IgG (1 h at 25˚C; 1:5,000; cat. no. 7074S; Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-goat IgG (1 h at 25˚C; 1:5,000; cat. no. sc-2020; Santa Cruz Biotechnology, Inc.). Specific complexes were visualized with an enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Little Chalfont, UK) as described previously (23) .
Proteomic analysis. To comprehensively investigate metabolic changes in BC cells treated with salirasib, proteomic analysis was performed using iMPAQT (19) . Proteins with downregulated expression were detected in salirasib-treated BC cells compared with untreated cells (fold change <0.5) and proteins that were common to both T24 and BOY were identified. The proteins were then categorized into Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways through GeneCodis analysis (genecodis.cnb.csic.es).
In vivo tumor xenograft model. To investigate in vivo effects of salirasib, a mixture containing 100 µl BOY cells (5x10 6 ) and 100 µl Matrigel Matrix (Corning Incorporated, Corning, NY, USA) was injected subcutaneously into one side flank of 9 female nude mice (BALB/c nu/nu; 8 weeks old; 16-19 g). The mice were randomly separated into salirasib-treated (n=5) and control (n=4) groups. Each breeding room was kept at a temperature of 23±1˚C and a humidity of 40-70%. The light/dark cycle was set to 12 h. Food and water was placed to be accessible from each cage. From the day following tumor implantation, salirasib (0.4 mg/mouse, i.p., daily) and control vehicle (0.5% ethanol, 100 µl/mouse, i.p., daily) treatment were administered for 25 days. Tumor sizes were measured twice weekly and tumor volumes were calculated as follows: Tumor volume = [(long axis length in millimeters/2) x (short axis length/2) 2 x π x 4]/3. All animal experiments were performed in accordance with institutional guidelines and were approved by the animal care review board of Kagoshima University (Kagoshima, Japan).
Statistical analysis. Data are presented as the mean ± standard deviation at least three independent experiments. The relationships between two groups were analyzed using Mann-Whitney U tests. The relationships between three or more variables and numerical values were analyzed using Bonferroni-adjusted Mann-Whitney U tests. All analyses were performed using Expert StatView software, version 5.0 (SAS Institute, Inc., Cary, NC, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Expression levels of HRAS in BC and BC cell lines.
The expression levels of HRAS were evaluated using TCGA data from BC samples (n=407) and normal samples (n=19). HRAS expression levels were significantly upregulated in tumor tissues compared with those in normal bladder epithelia (tumor, 10.314±0.813; normal, 9.707±0.826; P=0.0024, Mann-Whitney U tests; Fig. 1A ). Furthermore, HRAS expression was significantly upregulated in patients with BC with mutant HRAS compared with patients with wild-type HRAS (mutant HRAS, 11.277±0.805; wild-type HRAS, 10.267±0.788; P<0.0001, Mann-Whitney U tests) (Fig. 1B) . HRAS mRNA expression was also significantly upregulated in BC cell lines compared to patients with normal bladder tissues (T24, 5.960±0.344, P<0.0001; BOY, 7.528±1.506, P<0.0001; KK47, 2.934±0.464, P=0.0176; UMUC, 3.561±0.854, P=0.0034; Bonferroni-adjusted Mann-Whitney U tests; Fig. 1C ). Sequencing data from TCGA revealed that T24 cells had HRAS G12V (the substitution of glycine by valine at codon 12 in HRAS) and BOY cells had wild-type HRAS (Fig. 1D) .
Effects of HRAS knockdown on cell proliferation, migration, and invasion of BC cell lines.
To investigate the functional role of HRAS in BC cells, loss-of-function studies were performed using T24 and BOY BC cells transfected with three si-HRAS constructs (si-HRAS-1, si-HRAS-2 and si-HRAS-3). RT-qPCR analysis and western blot analysis indicated that these siRNAs effectively downregulated HRAS mRNA and protein expression in both cell lines ( Fig. 2A) . XTT assays demonstrated that cell proliferation was inhibited in si-HRAS transfectants compared with mock or siRNA-control transfectants (T24, mock 1.0±0.047, control 1. (Table Ⅰ) . GeneCodis analysis to categorize the proteins into KEGG pathways demonstrated that these proteins were included in 50 pathways that were significantly enriched following salirasib treatment (listed in descending order of corrected P-values in Table II ; Fig. 4) . 'Oxidative phosphorylation', 'pyrimidine metabolism', 'glycolysis/gluconeogenesis', 'pentose phosphate pathway', 'cysteine and methionine metabolism', 'glutathione metabolism', and 'purine metabolism' were significantly downregulated pathways in BC cells treated with salirasib. However, target genes of the RAS effector HIF-1α, including hexokinase 2, phosphoglycerate kinase 1, pyruvate kinase, muscle (PKM)1, PKM2 and lactate dehydrogenase A, showed only modest downregulation (fold change >0.5 in T24 and BOY cells) (Table III) (24) (25) (26) . Furthermore, RT-qPCR analysis and western blot analysis indicated that expression of HIF-1α was not downregulated in salirasib-treated BC cells (Fig. 5) (Fig. 6 ) on day 27 after tumor implantation.
Discussion
HRAS was the first human oncogene reported in the T24 BC cell line in 1982 (28) . Several reports have indicated that HRAS mutations critically influence tumorigenesis and development of BC (8, (29) (30) (31) (32) (33) . Haliassos et al (29) detected ΗRAS codon 12 point mutations in 66% of BC specimens and the mutant ΗRAS allele in the urine of 47% of patients with BC, Pandith et al (33) reported that HRAS single nucleotide polymorphism increases BC risk, and rare allele is a predictive marker of advanced bladder tumors. However, RAS had been considered to be 'undruggable' because the RAS protein lacked a druggable binding pocket until salirasib was produced. Salirasib inhibits RAS-dependent cell growth by dislodging all isoforms of RAS from the plasma membrane (11, 12) . The antitumor efficacy of salirasib has been demonstrated in several cell lines and xenograft models (17, (34) (35) (36) . Goldberg et al (34) demonstrated that salirasib induces pancreatic cancer cell death and tumor shrinkage in mice, and that salirasib was efficient and nontoxic for treatment of glioblastoma in a rat model (35) . Charette et al (36) reported that salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and in vivo through RAS and mTOR inhibition. Salirasib was evaluated as a single agent in two clinical trials; however, neither produced promising results in patients with KRAS mutation positive lung adenocarcinoma (13) or refractory hematologic malignancies (14) . Even though these clinical trials demonstrated the relative safety of salirasib, diarrhea, nausea and fatigue were the most common toxicities, and there were no grade 4 or 5 drug-associated adverse events or dose-limiting toxicity. On the other hand, results of a combination study of salirasib with gemcitabine to treat pancreatic adenocarcinoma were sufficiently encouraging to warrant further investigation (15, 16) .
Although the efficacy of salirasib has been reported for several types of cancers, to the best of our knowledge, this is the first report concerning the effect of salirasib in BC. Two BC cell lines were used to evaluate the ability of salirasib to target HRAS. T24 carries the HRAS G12V mutation (substitution of glycine by valine at codon 12 of HRAS) and sequencing data demonstrated that BOY cells have wild-type HRAS. siRNA-induced HRAS knockdown and salirasib inhibition of HRAS exerted tumor suppressive effects regardless of HRAS mutational status in vitro, which was consistent with several previously published results demonstrating a lack of correlation between RAS mutational status and response to RAS-targeting therapy (37,38). However, salirasib still required relatively high concentrations to achieve a tumor-suppressive effect in vitro, and exhibited no tumor-suppressive effects in vivo. It had been reported that oncogenic RAS predominantly affects the metabolic reprogramming of cancer cells through the upregulation of HIF-1α, one of target genes of RAS (5). Although salirasib is known to competitively block intracellular signaling via the RAS cascade, there are no reports concerning comprehensive metabolomic analysis of salirasib mechanisms. In the current study, proteomic analysis was performed using iMPAQT to investigate metabolic changes in salirasib-treated BC cells. Pathway analysis using the proteomic data indicated that 50 pathways were significantly downregulated following salirasib treatment of BC cells, including 'Oxidative phosphorylation', 'Glycolysis/gluconeogenesis', and 'Pentose phosphate pathway'. However, proteomic analysis showed that the expression of proteins downstream of HIF-1α were not significantly downregulated. Furthermore, HIF-1α expression was not efficiently suppressed in salirasib-treated BC cells, although it was previously reported that salirasib suppressed HIF-1α expression (27) . Therefore, downregulation of RAS target genes in in vitro assays involving BC cell lines may require a high concentration of salirasib, and this need for high concentrations was responsible for the lack of tumor suppressive effects observed in the BC xenograft mouse model. In this study, whether factors downstream of HIF-1α were insufficiently downregulated in the tumors from animal experiments was not analyzed by iMPAQT, because iMPAQT is so sensitive that contamination of surrounding tissues adjacent to tumor tissue may make the interpretation of the results difficult. However, these analyses of micro-dissected in vivo samples will be performed in the future. Recently, a novel RAS inhibitor developed using an innovative approach was reported to inhibit tumor growth in animal models of RAS-dependent cancers at low concentrations (39) . This novel RAS inhibitor was computationally designed to target multiple sites on RAS proteins, thus enabling sufficient affinity and selectivity for pharmacological RAS inhibition. This new inhibitor may provide successful targeting of RAS in the near future. Therefore, clinical trials with these inhibitors or next-generation RAS inhibitors are required to improve cancer treatment options in the near future.
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In conclusion, the current study demonstrated that salirasib and siRNA-induced HRAS knockdown produced tumor suppressive effects regardless of HRAS mutational status in BC cell lines. However, high concentrations of salirasib were required to inhibit cell proliferation, migration and invasion activity in vitro, and the same high concentrations exhibited no tumor suppressive effects in vivo. Proteomic analysis revealed that several metabolic pathways were significantly downregulated in BC cells treated with salirasib. However, salirasib treatment of BC cells did not significantly affect expression of genes targeted by HIF-1α in BC cells. These findings provide novel information concerning the mechanism of salirasib effects, and suggest that novel therapeutics involving combination therapies of salirasib with other inhibitors, or the newly-identified novel RAS inhibitor, may be effective for treating BC and other types of cancer. Kagoshima University, Kagoshima, Japan) for laboratory assistance.
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